Indapta Therapeutics, Inc.

Indapta Therapeutics Raises $22.5 Million to Advance NK Cell Therapy

5 months ago

• Indapta Therapeutics has secured $22.5 million in funding to accelerate clinical trials of its allogeneic Natural Killer (NK) cell therapy, IDP-023. • Phase 1 trial of IDP-023 in Non-Hodgkin’s Lymphoma and Multiple Myeloma has completed the safety run-in, showing promising early results. • FDA has cleared Indapta's IND for IDP-023 combined with ocrelizumab in progressive multiple sclerosis, with Phase 1 trial planned for Q1 2025. • Indapta's approach differentiates itself through multiple mechanisms, including enhanced B cell depletion and targeting of autoreactive T and B cells.